JAZZ Collar Strategy
JAZZ (Jazz Pharmaceuticals plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc.
JAZZ (Jazz Pharmaceuticals plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $15.64B, a trailing P/E of 16.72, a beta of 0.32 versus the broader market, a 52-week range of 115.12-265.05, average daily share volume of 899K, a public-listing history dating back to 2007, approximately 3K full-time employees. These structural characteristics shape how JAZZ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.32 indicates JAZZ has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on JAZZ?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
JAZZ snapshot
As of August 14, 2026, spot at $244.17, ATM IV 41.40%, IV rank 26.55%, expected move 11.87%. The collar on JAZZ below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this collar structure on JAZZ specifically: IV regime affects collar pricing on both sides; compressed JAZZ IV at 41.40% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 11.87% (roughly $28.98 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated JAZZ expiries trade a higher absolute premium for lower per-day decay. Position sizing on JAZZ should anchor to the underlying notional of $244.17 per share and to the trader's directional view on JAZZ stock.
JAZZ collar setup
The JAZZ collar below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With JAZZ at $244.17 on that close, the first option leg uses a $260.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed JAZZ chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 JAZZ shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $244.17 | long |
| Sell 1 | Call | $260.00 | $6.65 |
| Buy 1 | Put | $230.00 | $6.20 |
JAZZ collar risk and reward
- Net Premium / Debit
- -$24,372.00
- Max Profit (per contract)
- $1,628.00
- Max Loss (per contract)
- -$1,372.00
- Breakeven(s)
- $243.72
- Risk / Reward Ratio
- 1.187
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
JAZZ collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on JAZZ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$1,372.00 |
| $54.00 | -77.9% | -$1,372.00 |
| $107.98 | -55.8% | -$1,372.00 |
| $161.97 | -33.7% | -$1,372.00 |
| $215.95 | -11.6% | -$1,372.00 |
| $269.94 | +10.6% | +$1,628.00 |
| $323.93 | +32.7% | +$1,628.00 |
| $377.91 | +54.8% | +$1,628.00 |
| $431.90 | +76.9% | +$1,628.00 |
| $485.89 | +99.0% | +$1,628.00 |
When traders use collar on JAZZ
Collars on JAZZ hedge an existing long JAZZ stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
JAZZ thesis for this collar
The market-implied 1-standard-deviation range for JAZZ extends from approximately $215.19 on the downside to $273.15 on the upside. A JAZZ collar hedges an existing long JAZZ position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current JAZZ IV rank near 26.55% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on JAZZ at 41.40%. As a Healthcare name, JAZZ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to JAZZ-specific events.
JAZZ collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. JAZZ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move JAZZ alongside the broader basket even when JAZZ-specific fundamentals are unchanged. Always rebuild the position from current JAZZ chain quotes before placing a trade.
Frequently asked questions
- What is a collar on JAZZ?
- A collar on JAZZ is the collar strategy applied to JAZZ (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With JAZZ stock at $244.17 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed JAZZ chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are JAZZ collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the JAZZ collar priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 41.40%), the computed maximum profit is $1,628.00 per contract and the computed maximum loss is -$1,372.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a JAZZ collar?
- The breakeven for the JAZZ collar priced on this page is roughly $243.72 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The JAZZ market-implied 1-standard-deviation expected move in the same options snapshot is approximately 11.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on JAZZ?
- Collars on JAZZ hedge an existing long JAZZ stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current JAZZ implied volatility affect this collar?
- JAZZ ATM IV is at 41.40% with IV rank near 26.55%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.